New Study Finds Increased Risk Of NuvaRing Stroke and Heart Attack
Bernstein Liebhard LLP reports on a June 14, 2012 study which found that combined hormone birth control products such as NuvaRing were linked to a higher risk of heart attack and stroke, adding to growing concerns about NuvaRing adverse effects.
New York, New York (PRWEB) June 19, 2012
Bernstein Liebhard LLP, a nationwide law firm representing clients who experienced NuvaRing adverse effects, reports on a June 14, 2012 study published in the New England Journal of Medicine that found an increased risk of heart attack or stroke in combined hormonal birth control products such as NuvaRing.* Danish researchers analyzed 15 years of data from more than 1.6 million women aged 15 to 49 and compared the heart risks from various forms of hormonal contraception. Researchers found that women who took combination estrogen and progestin birth control pills such as Yaz and Yasmin experienced heart attacks and strokes up to twice as often as women who did not use hormonal contraception.** The risks were up to three times higher for users of NuvaRing and Ortho Evra patches than non-users, and were even more pronounced in women with diabetes, high blood pressure and those over age 35. While the absolute risk of a heart attack or stroke from birth control products remains small, the study adds to growing concern surrounding NuvaRing adverse effects.
Lawsuits Mounting Over NuvaRing Adverse Effects
Data from the same study were used in a report in the British Medical Journal in May, which focused on the increased cardiovascular risks from NuvaRing and the Ortho Evra patch.*** In October 2011, the U.S. Food and Drug Administration (“FDA”) released a study that found that several new forms of birth control, including NuvaRing, led to increased risks of blood clots. The study found that the use of NuvaRing and Ortho Evra raised the risk of venous thrombosis by about 55 percent.
Merck & Co., the manufacturer of NuvaRing, is currently defending over 950 NuvaRing lawsuits.***** Plaintiffs in the lawsuits allege that the company sold a defectively designed product and failed to adequately warn users of the increased risk of NuvaRing adverse effects, such as stroke and heart attack. The majority of these cases are pending in a federal multidistrict litigation in the U.S. District Court for the Eastern District of Missouri before Judge Rodney Sippel (MDL No. 1964), and in a coordinated proceeding in Bergen County Superior Court of New Jersey before Judge Brian R. Martinotti (Docket No. BER-L-3081-09).
Those who experienced NuvaRing adverse effects may be entitled to compensation for medical bills, pain and suffering, lost wages and other injuries. Our lawyers and staff understand the sensitive nature of the complications caused by NuvaRing and will answer your questions in a caring and sympathetic manner. For more information about filing a lawsuit, contact an attorney at Bernstein Liebhard LLP at (877) 779-1414 or at info(at)consumerinjurylawyers(dot)com.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs´ Hot List,” recognizing the top plaintiffs´ firms in the country, for the past nine consecutive years. Only two firms in the country have been selected for the Hot List nine years in a row.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2012 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Amy L. Abate. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
For the original version on PRWeb visit: http://www.prweb.com/releases/prwebbernstein-liebhard/nuvaring-adverse-effects/prweb9621424.htm